Carbatrol

Carbatrol is a brand name of carbamazepine, approved by the FDA in the following formulation(s):

CARBATROL (carbamazepine - capsule, extended release; oral)

• 
  Manufacturer: SHIRE
  
  Approval date: September 30, 1997
  
  Strength(s): 100MG ^[AB], 200MG ^[AB], 300MG ^[RLD][AB]

Has a generic version of Carbatrol been approved?

A generic version of Carbatrol has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Carbatrol and have been approved by the FDA:

carbamazepine capsule, extended release; oral

• 
  Manufacturer: APOTEX INC
  
  Approval date: November 25, 2011
  
  Strength(s): 100MG ^[AB], 200MG ^[AB], 300MG ^[AB]


• 
  Manufacturer: NOSTRUM
  
  Approval date: May 20, 2011
  
  Strength(s): 100MG ^[AB], 200MG ^[AB], 300MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Carbatrol. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
  Patent 5,326,570
  Issued: July 5, 1994
  Inventor(s): Rudnic; Edward M. & Belendiuk; George W.
  Assignee(s): Pharmavene, Inc.
  The present invention relates to a composition and method of treating a patient by administering carbamazepine in a pharmaceutical dosage form capable of maintaining the patient's blood concentration at from about 4 .mu.g/ml to about 12 .mu.g/ml over at least a 12 hour period, where the blood concentration of carbamazepine does not vary by more than 60 percent.
  
  Patent expiration dates:
  
  
  • July 23, 2011
    
    ✓ 
    Patent use: TREATMENT OF EPILEPSY TWICE DAILY. TREATING A PATIENT BY ADMINISTERING CARBAMAZEPINE IN A DOSAGE FORM CAPABLE OF MAINTAINING BLOOD CONCENTRATION FROM 4-12MCG/ML OVER 12 HOURS
  
  



• 
  Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
  Patent 5,912,013
  Issued: June 15, 1999
  Inventor(s): Rudnic; Edward M. & Belendiuk; George W. & McCarty; John & Wassink; Sandra & Couch; Richard A.
  Assignee(s): Shire Laboratories, Inc.
  The present invention relates to a composition and method of treating a patient by administering carbamazepine in a pharmaceutical dosage form capable of maintaining the patient's blood concentration at from about 4 .mu.g/ml to about 12 .mu.g/ml over at least a 12 hour period, where the blood concentration of carbamazepine does not vary by more than 60 percent.
  
  Patent expiration dates:
  
  
  • June 15, 2016
    
    ✓ 
    Patent use: NEUROLOGICAL AND OTHER DISORDERS (TREATMENT OF EPILEPSY, BID ORAL DOSING)
  
  

See also...

• Carbatrol Sustained-Release Capsules Consumer Information (Wolters Kluwer)
• Carbatrol Consumer Information (Cerner Multum)
• Carbatrol Advanced Consumer Information (Micromedex)
• Carbamazepine Consumer Information (Drugs.com)
• Carbamazepine Consumer Information (Wolters Kluwer)
• Carbamazepine Chewable Tablets Consumer Information (Wolters Kluwer)
• Carbamazepine Suspension Consumer Information (Wolters Kluwer)
• Carbamazepine Sustained-Release Capsules Consumer Information (Wolters Kluwer)
• Carbamazepine Sustained-Release Tablets Consumer Information (Wolters Kluwer)
• Carbamazepine Consumer Information (Cerner Multum)
• Carbamazepine Advanced Consumer Information (Micromedex)
• Carbamazepine AHFS DI Monographs (ASHP)